Menu
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #1131 to learn about how we are enabling breakthrough innovations in cancer research.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to your launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
Check out the full program:
Nov 20 | Corporate Workshops | 214 Level 2
11:00 – 11:50 am
Insights with Impact: Empowering Laboratories with a Decentralized MSK Solution for CGP
Presenters:
12:00 – 12:50 pm
Strategic Collaborations for Expanding Liquid Biopsy Use Globally
Presenters:
Nov 23 | Poster Session
9:15 – 10:15 am
Analytical Validation of the Decentralized MSK-ACCESS® powered with SOPHiA DDM™ Solution
Authored by:
Florian Klemm 1*, Fuad Mohammad 1, Fabio De Martino 1, Yvan Wenger 1, Jacklyn Casanova-Murphy 2, Anita Bowman 2, Brian Loomis 2,3, A. Rose Brannon 2, Michael F. Berger 2,3, Zhenyu Xu 1
1 SOPHiA GENETICS SA, Data Science Department, Rolle, Switzerland
2 Memorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, NY
3 Memorial Sloan Kettering Cancer Center, Center for Molecular Oncology, New York, NY
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
